Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioblastoma × azeliragon × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Temozolomide 154 Bevacizumab 88 Radiotherapy 75 Radiation 23 Magnetic Resonance Spectroscopy 23 Lomustine 18 Irinotecan 18 pembrolizumab 17 Surgical Procedures, Operative 16 Carmustine 16 Erlotinib Hydrochloride 12 Nivolumab 11 Specimen Handling 10 Aminolevulinic Acid 10 sargramostim 9 Thalidomide 9 Chemotherapy, Adjuvant 9 Carboplatin 9 Immunoglobulin G 7 Filgrastim 7 Etoposide 7 Drug Therapy 7 Disulfides 7 Cilengitide 7 Sunitinib 6 Sorafenib 6 O(6)-benzylguanine 6 Cyclophosphamide 6 antineoplaston AS 2-1 5 antineoplaston A10 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05986851 2026-03-31

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡